Are Statins Optimally Prescribed to Reduce Stroke Risk in Patients with Hypercholesterolaemia?
A population-based Longitudinal Study Using Electronic Health Records in South London (2005–2021)

Marc Delord[1,*], Mark Ashworth[1], and Abdel Douiri[1]

[1]School of Life Course & Population Sciences, Department of Population Health Sciences, King's College London, London, United Kingdom
*Correspondence: marc.delord@kcl.ac.uk, Tel: +44 20 7848 8710

Abstract

Background: We aim to evaluate the impact of statin prescription on the risk of stroke in patients with hypercholesterolaemia.

Methods: We analysed electronic health records from patients with hypercholesterolaemia, registered in 41 general practices in south London between 2005 and 2021. Association between cumulative incidence of stroke and statin prescription, adjusted for history of heart diseases (HHD), was evaluated using a proportional subdistribution hazard model. Restricted mean stroke-free survival was evaluated in patients with stroke relative to statin prescription. Association between statin prescription and patients' sociodemographics was evaluated using logistic regression.

Results: Of the 849,968 registered patients, 168,570 (19.5%) had records of hypercholesterolaemia. Among them, 33.5% were prescribed statins, 2.6% had a record of stroke, and 50.6% were female. 31.7%, 16.2%, 7.9%, and 3.4% had records of hypertension, diabetes, HHD, and atrial fibrillation, respectively. Statin prescription was associated with reduced hazard of stroke (adjusted subdistribution hazard ratio: 0.87, (95% confidence interval (CI): 0.81-0.93), p<0.001) or delayed onset of stroke, the restricted mean stroke-free survival at record of hypercholesterolaemia being 3.8 years longer in patients with prescribed statins (95% CI: from 3.4 to 4.1, p < 0.001). Statins were less likely prescribed to female patients and patients of Black ethnicity (Odds-ratio: 0.70, 95% CI: 0.68-0.72, p<0.001 and OR: 0.81, 95% CI: 0.78-0.83, p<0.001, respectively).

Conclusion: The benefit–risk balance of statins should be re-evaluated to optimise stroke prevention in patients with hypercholesterolaemia, while further efforts should be made to address disparities observed in statin prescription across gender groups and ethnic groups.

Keywords:

Stroke; Hypercholesterolemia; Statin therapy; Electronic Health Records; Gender Disparity; Ethnic Disparity

---

key messages

What is already known on this topic:

If statins are widely recognised for their efficacy in reducing the risk of major cardiovascular events, including stroke, analysing their effectiveness in patients with hypercholesterolaemia remains challenging due to the complex relationship between hypercholesterolaemia and stroke. Moreover, questions remain regarding optimal prescription practices, particularly across different demographic groups, and the impact of statins on long-term stroke prevention.

What this study adds:

This study demonstrates the effectiveness of statin therapy in stroke prevention by either lowering the incidence of stroke or delaying its onset in patients with hypercholesterolaemia, extending stroke-free survival at record of hypercholesterolaemia by an average of 3.8 years. It also highlights disparities in statin prescription, with women and patients of Black ethnicity being less likely to receive statins.

How this study might affect research, practice, or policy:

The findings suggest the need for greater attention to disparities in statin prescription practices, particularly across gender and ethnic groups, and the opportunity of expanding statin prescription to patients with untreated hypercholesterolaemia in accordance with current recommendations.

Introduction

The relationship between hypercholesterolaemia and stroke has been described as complex [1]. This complexity is due to interacting factors such as cholesterol composition [2], stroke subtypes [2–4], patients' age [5], and the confounding effect of lipid-lowering therapies, particularly statins. For instance, the risk of stroke in patients with familial hypercholesterolaemia (FH), which is associated with high low-density lipoprotein cholesterol (LDL-C) [6], is significantly reduced by the use of statins [7], and recent population-based studies did not report an excess risk of stroke in patients with FH [8, 9]. Despite initial concerns regarding the paradoxical association

between cholesterol levels and haemorrhagic stroke [3, 10], statins are considered safe and effective to reduce total stroke risk [5, 11–14].

Importantly, statins reduce the risk of major vascular events—including stroke—irrespective of patients' age, sex, or cardiovascular risk [12, 13], lower risks being associated with more intensive regimens [13]. Statins are also considered remarkably safe drugs, with possible risks of haemorrhagic stroke being outweighed by the protective effect against ischaemic stroke and coronary artery disease [15]. Concerns about statin-related muscle pain were explored in randomised trials suggested no significant difference in muscle symptoms between statin and placebo use [16, 17]. Other significant but rare adverse effects of statins include new-onset diabetes [18] or muscle damage such as myopathy or rhabdomyolysis [15].

Overall, lifetime statin regimens have proven to be cost-effective [19] and are currently recommended for patients with a history of cardiovascular diseases, or in primary prevention based on factors such as pre-treatment cardiovascular risk, LDL-C levels, or comorbidity [20–23]. Since 2014, the National Institute for Health and Care Excellence (NICE) guidelines for primary prevention recommended statin prescription in patients aged 40 and older with a 10-year cardiovascular risk above 10% (QRISK2 > 10%) [24]. This threshold was set to prevent cardiovascular events in patients considered at moderate risk. These guidelines also suggested considering statins if other factors such as family history, socioeconomic factors, or patient preference might indicate an underestimated cardiovascular risk. The 2023 update reinforces the importance of shared decision-making, allowing statin use even for patients with a risk lower than 10% if the patient has an informed preference or if the risk might be underestimated. This update also recommends using the QRISK3 tool for cardiovascular risk assessment, which accounts for additional risk factors such as chronic kidney disease, severe mental illness, and migraine, and emphasises flexibility and patient autonomy in making treatment decisions [25, 26].

Despite the favourable benefit–risk profile of statins, concerns exist regarding treatment adherence in primary or secondary cardiovascular disease prevention [27]. Consequently, optimal lowering of LDL-C is not achieved within two years in over half of the patients initiated on statin therapy, significantly elevating their risk of future cardiovascular disease [28]. On the other hand, the effectiveness of statins for primary stroke prevention [29], even in patients without substantial cardiovascular risk factors [13], suggests a potential for broader use of statins in primary prevention of stroke in patients with hypercholesterolaemia.

In line with these observations, our objective in this study is to better understand the association between the onset of stroke and statin prescription in patients with hypercholesterolaemia, using routinely collected electronic health records in a multiethnic, youthful, and urban population. Accordingly, we have estimated the impact of statin prescription on the cumulative incidence of stroke and the restricted mean stroke-free survival at record of hypercholesterolaemia. The association between statin prescription and patients' sociodemographic characteristics was also evaluated.

Method

Study participants

The study was conducted in the Lambeth borough in South London, characterised by a multi-ethnic, youthful, and deprived population. We utilised primary care electronic health records from adult patients aged over 18 and registered in one of the 41 Lambeth general practices between April 2005 and April 2021. The proportion of patients dropping out from the anonymised data-sharing scheme was 3.2%. These patients were not included in the study.

Primary care data

Electronic health records included the date of diagnoses of 18 long-term conditions coded in accordance with the Quality and Outcomes Framework (QOF), based on QOF38 definitions [30]. Long-term conditions included stroke, hypertension, diabetes, hypercholesterolaemia (total cholesterol > 5.0 mmol/L), atrial fibrillation, heart failure, myocardial infarction, chronic kidney disease stage 3 to 5, and transient ischaemic attack. Other information included gender (self-ascribed), ethnicity (Asian ethnicity, Black ethnicity, mixed ethnicity, other/unknown ethnicity, and White ethnicity), 'ever smoking' status, and the Index of Multiple Deprivation (IMD) 2019 (from 1-most deprived to 5-least deprived, based on seven domains of deprivation including income, employment, education, health, crime, housing, and quality of living environment). From available records, long-term conditions eligible for primary prevention include diabetes and chronic kidney disease stage 3 to 5. Likewise, patients eligible for secondary prevention are patients with a history of cardiovascular disease, defined as coronary heart disease, heart failure, stroke, peripheral arterial or vascular disease, myocardial infarction, atrial fibrillation, or transient ischaemic attack. Of note, patient age was implicitly accounted for through the dating of records of long-term conditions.

Statistical analyses

Long-term conditions, sociodemographic variables, and other variables were displayed as frequencies or median and interquartile range as appropriate. Cumulative incidence of stroke versus death was estimated using the Kalbfleisch and Prentice method [31]. The mean difference in stroke-free survival was computed from the restricted mean stroke-free survival between the considered groups at record of hypercholesterolaemia. The association between stroke and statin prescription, sociodemographic covariates, and stroke risk factors in patients with hypercholesterolaemia was evaluated using univariable logistic regression. The association between the cumulative incidence of stroke versus death and statin prescription, sociodemographic covariate, and stroke risk factors in patients with hypercholesterolaemia was evaluated using univariable and multivariable subdistribution hazard ratio (SDHR) computed from Fine and Gray's proportional subdistribution hazard model [32]. The association between statin prescrip-

tion, sociodemographic covariates, and stroke risk factors in patients with hypercholesterolaemia was evaluated using multivariable odds ratios.

Multivariable logistic models were adjusted by time to stroke in patients with a record of stroke and time to last follow-up for other patients (censored time to stroke). Indicators of all covariates were censored at time of stroke in patients with a record of stroke or time to last follow-up for other patients. The hypothesis of proportional subdistribution hazard of stroke with respect to statin prescription was visually checked from the complementary log-log transformation of the cumulative incidence in both groups. Patients with missing covariates were excluded from models where these covariates were used as confounders.

All computations were carried out using the R language and environment for statistical computing (version 4.3.0 (2023-04-21)) [33].

Ethics

This study was conducted in accordance with the Declaration of Helsinki. Data were provided by the Lambeth DataNet upon approval for the analysis of fully anonymised data by the Lambeth Clinical Commissioning Group. All patients were informed through 'Fair Processing Notices' of the potential use of collected electronic health records in 'secondary data analysis' and were given the option to opt out of the data-sharing scheme [34]. Accordingly, this study was exempt from ethics committee approval and individual consent requirements as per the National Institute for Health (NIH) Health Research Authority (HRA) guidelines for research using anonymised primary care data in the United Kingdom.

Patient and public involvement

This research project actively involved patients and the public at several stages, including study design and dissemination strategies. Feedback was gathered from two Patient and Public Involvement groups, organised by the NIHR Biomedical Research Centres, including stroke and cardiovascular patient groups. These consultations were invaluable in shaping our approach to data use, confidentiality, and research ethics.

To ensure transparency and better inform the public about Lambeth DataNet research outcomes, the results of this research will be disseminated widely. Efforts will involve sharing findings with the public through accessible platforms, including community websites and publications, as recommended by the Lambeth DataNet engagement groups. The results will also be communicated to local community groups, healthcare professionals, and Patient and Public Involvement groups to continue the discussion and identify further areas of research.

Results

Patient characteristics

Patient characteristics are summarised in Table 1. Briefly, of 166,124 patients with hypercholesterolaemia, 8.3%, 21.9%, 3.7%, and 54.4% self-identified as being of either Asian, Black, Mixed, or White ethnicity, and 11.6% were of other or unknown ethnicity. Female gender (self-ascribed) represented 50.6%. Gender was not declared by three patients. The IMD was available for 164,322 (98.9%) patients. Patients of White and Asian ethnicity had similar IMD profiles, whereas patients of Black ethnicity were overrepresented in IMD quintiles 1 and 2 (most deprived) and conversely less represented in quintiles 4 and 5 (least deprived).

Risk factors, statin prescription, and stroke

Patients with hypercholesterolaemia and stroke represented respectively 19.54% (n=166124) and 1.15% (n=9847) of all registered patients (n=849,968). Among them, 33.5% were prescribed statins versus 1.3% in other patients, and 4,390 patients (2.6%) had a record of stroke. These patients represented also 44.6% of all patients with stroke in the registry. Hypertension (67.5%) and diabetes (29.7%) were the two major metabolic stroke risk factors recorded for these patients, along with a history of heart disease (25.1%) and atrial fibrillation (12.6%). Patients of Black ethnicity were overrepresented among patients with a record of stroke (26.6% vs. 21.8%), and conversely, patients of White ethnicity were slightly underrepresented (52.4% vs. 54.5%). Statins were prescribed in 33.5% of patients with hypercholesterolaemia and 32.9% of patients with stroke. The proportion of patients with a record of diabetes diagnosed after the age of 40 or lasting more than 10 years, or chronic kidney disease stages 3 to 5, was 19.4%, of whom 79.5% were prescribed statin therapy in accordance with current guidelines on primary prevention (Table 1). Likewise, the proportion of patients with a history of cardiovascular disease, and therefore eligible for statin therapy in secondary prevention, was 10.5%. Among these patients, 81.4% were prescribed statins (Table 1).

Cumulative incidence of stroke

Cumulative incidence of stroke (vs. death) in patients with hypercholesterolaemia and prescribed statins vs. patients without prescribed statins is displayed in Figure 1. The cumulative incidence at 40, 60, and 80 years was 0.03%, 1.02%, and 6.88% in patients with prescribed statins versus 0.05%, 1.23%, and 7.23% for other patients.

Before testing the hypothesis of equal subdistribution hazard in patients with or without statin prescription using the Fine and Gray's proportional subdistribution hazard model, visual inspection of the complementary log-log transformation of the cumulative incidence of stroke in both groups of patients suggested non-proportionality of the subdistribution hazard before the age of 30 and a crossing pattern after the age of 82. Accordingly, Fine and Gray's models

were restricted to patients from 30 to 82 years old, which represented 88.6% of patients with hypercholesterolaemia. Using this subset of patients, the SDHR of statin prescription was 0.96 (95% confidence interval (CI) from 0.90 to 1.03, p = 0.27, Supplementary Table S1. This result indicates that the hypothesis of differential cumulative incidence of stroke in patients with or without statin prescription could not be rejected at a 5% type I error rate in patients from 30 to 82 years old.

Other patients							
At risk	105487	86765	58278	30060	11661	5147	1609
#stroke	9	52	263	620	981	1354	1630
Patients with statins prescriptions							
At risk	55380	54200	49994	40219	24660	11558	2591
#stroke	2	19	115	475	1079	1869	2537

Figure 1: *Cumulative incidence of stroke and death in patients with hyper-cholesterolaemia and prescribed statins versus other patients*

Association between statin prescription and stroke

Supplementary Table S1 displays univariable odds ratios of stroke and subdistribution hazard ratios of the cumulative incidence of stroke associated with statin prescription, sociodemographic covariates, and stroke risk factors (in patients from 30 to 82 years old). Alone, statin prescription was strongly associated with stroke, with an odds ratio of 3.25 (95% confidence interval (CI): from 3.04 to 3.48, p < 0.001). Black vs. White ethnicity and other stroke risk factors were also positively associated with stroke. Levels of deprivation from 2 to 5 (least deprived) were associated with lower odds ratios of stroke. The univariable subdistribution hazard ratios provide a different pattern. Female gender and levels of deprivation from 2 to 5 (least deprived) were significantly associated with a lower cumulative incidence of stroke, unlike statin prescription, ever-smoking status, history of atrial fibrillation, or heart disease. Black, Asian, and Mixed ethnicity, as compared to White ethnicity, were also associated with higher cumulative incidences of stroke.

Coefficients of the multivariable proportional subdistribution hazard model are depicted in Figure 2. In this model, statin prescription, female gender, and levels of deprivation from 2 to 5 (least deprived) were significantly associated with a lower cumulative incidence of stroke. On the the other

Variable		N	SDHR (multivariable)		p
Statins	No	109250		Reference	
	Yes	55069		0.87 (0.81, 0.93)	<0.001
Gender	Male	81121		Reference	
	Female	83198		0.77 (0.72, 0.81)	<0.001
Ethnicity	White	89364		Reference	
	Black	36014		1.29 (1.20, 1.40)	<0.001
	Asian	13716		1.19 (1.06, 1.34)	0.004
	Mixed	6078		1.30 (1.09, 1.55)	0.004
	Other	4609		1.12 (0.88, 1.43)	0.360
	Unknown	14538		1.02 (0.92, 1.14)	0.680
IMD local quintile	1 (most deprived)	35817		Reference	
	2	34494		0.90 (0.82, 0.98)	0.015
	3	29128		0.87 (0.79, 0.95)	0.003
	4	30427		0.83 (0.75, 0.91)	<0.001
	5 (least deprived)	34453		0.84 (0.77, 0.92)	<0.001
Smoking ever	No	75784		Reference	
	Yes	88535		1.03 (0.97, 1.10)	0.380
Hypertension	No	112220		Reference	
	Yes	52099		1.32 (1.23, 1.41)	<0.001
Diabetes	No	137670		Reference	
	Yes	26649		1.05 (0.98, 1.13)	0.190
Atrial Fibrillation	No	158657		Reference	
	Yes	5662		1.06 (0.96, 1.16)	0.250
History of heart diseases	No	151374		Reference	
	Yes	12945		1.03 (0.95, 1.11)	0.490

0.8   1   1.3

Figure 2: Multivariable subdistribution hazard ratio of stroke associated with statin prescription, adjusted for sociodemographic and stroke risk factors, in patients with hypercholesterolaemia aged 30 to 82 years

hand, Black, Asian, and Mixed ethnicity, as compared to White ethnicity, and hypertension were significantly associated with a higher cumulative incidence of stroke.

Time to stroke in patients with stroke and hypercholesterolaemia

Figure 3 displays the cumulative incidence of stroke in patients with hypercholesterolaemia and a record of stroke from time to record of hypercholesterolaemia. The restricted mean stroke-free survival at record of hypercholesterolaemia was 5.3 years in patients without statin prescription and 9.08 years in patients with statin prescription. Overall, the difference in restricted mean stroke-free survival at record of hypercholesterolaemia between patients with prescribed statins and other patients was 3.8 years (95% CI: from 3.4 to 4.1, p < 0.001).

Statins prescription in patients with hypercholesterolaemia

Figure 4 displays the multivariable odds ratio of statin prescription status associated with patients' sociodemographic characteristics and stroke risk factors in patients with hypercholesterolaemia. As expected, statin prescription is strongly associated with stroke risk factors, particularly diabetes, history of heart disease, and hypertension, and, to a lesser extent, ever-smoking

Patients with statins prescriptions							
At Risk	2681	1905	1098	476	100	16	4
Events	0	776	1583	2205	2581	2665	2677
Other patients							
At Risk	1709	741	272	67	13	2	1
Events	0	968	1437	1642	1696	1707	1708

Figure 3: *Cumulative incidence of stroke in patients with stroke and hypercholesterolaemia from time to record of hypercholesterolaemia*

status. On the other hand, patients with atrial fibrillation are less likely to have a record of statin prescription. Patients of Black ethnicity are less likely to be prescribed statin therapy compared to patients of White ethnicity, whereas patients of Asian ethnicity are more likely to be prescribed statins compared to patients of White ethnicity. Finally, female patients are also less likely to be prescribed statins than male patients.

Discussion

In this study, we set out to better understand the association between the onset of stroke and statin prescription in patients with hypercholesterolaemia, using routinely collected electronic health records in a multiethnic, youthful, and urban population. Our results exemplify the complexity of the relationship between hypercholesterolaemia and stroke, but also the preventive effect of statins against stroke in patients with hypercholesterolaemia. This complexity is exemplified by the association between statin prescription and risk of stroke. In a simple logistic model, statin prescription was strongly associated with the risk of stroke. In this setting, however, statin prescription is a marker of hypercholesterolaemia and other stroke risk factors. The unadjusted subdistribution hazard ratio, on the other hand, does not show any effect of statin prescription on the cumulative incidence of stroke in patients with hypercholesterolaemia. This difference between both measurements of the effect of statin prescription on the risk of stroke can be explained by the implicit consideration of the age at onset of stroke, the age at censoring, and at patients' death when computing the subdistribution hazard ratio.

The apparent absence of an effect of statins is illustrated in Figure 1, which depicts comparable

Variable		N	Odds ratio		p
Censored time to stroke		164319		1.06 (1.06, 1.06)	<0.001
Gender	Male	81121		Reference	
	Female	83198		0.70 (0.68, 0.72)	<0.001
Ethnicity	White	89364		Reference	
	Black	36014		0.81 (0.78, 0.83)	<0.001
	Asian	13716		1.61 (1.53, 1.69)	<0.001
	Mixed	6078		0.97 (0.90, 1.05)	0.491
	Other	4609		1.15 (1.06, 1.25)	0.001
	Unknown	14538		0.72 (0.69, 0.76)	<0.001
IMD local quintile	1 (most deprived)	35817		Reference	
	2	34494		0.99 (0.95, 1.03)	0.715
	3	29128		0.96 (0.92, 1.00)	0.047
	4	30427		0.98 (0.94, 1.02)	0.403
	5 (least deprived)	34453		0.94 (0.90, 0.98)	0.005
Smoking ever	No	75784		Reference	
	Yes	88535		1.28 (1.25, 1.32)	<0.001
Hypertension	No	112220		Reference	
	Yes	52099		2.93 (2.84, 3.01)	<0.001
Diabetes	No	137670		Reference	
	Yes	26649		10.57 (10.17, 10.99)	<0.001
Atrial Fibrillation	No	158657		Reference	
	Yes	5662		0.79 (0.74, 0.86)	<0.001
History of heart diseases	No	151374		Reference	
	Yes	12945		5.26 (4.96, 5.59)	<0.001

***Figure 4:** Multivariable odds ratio of statin prescription associated with sociodemographics and stroke risk factors in patients with hypercholesterolaemia*

cumulative incidence of stroke in patients with hypercholesterolaemia according to statin therapy prescription. Even with a possible immortal time bias favouring patients with statin prescription, due, for instance, to higher survival, and a subsequent increased probability of being exposed to statins in that group, the effect of statin prescription remains unclear in these patients. On the other hand, the lower cumulative incidence of death observed in patients prescribed statins suggests that these patients remain at risk of stroke for a prolonged period and may ultimately experience a stroke at an older age.

Nevertheless, the subdistribution hazard model, adjusted for sociodemographic covariates and stroke risk factors, shows a clear and significant downward effect associated with statin prescription on the cumulative incidence of stroke in patients with hypercholesterolaemia. In addition, statin prescription in patients with stroke and hypercholesterolaemia is associated with a restricted mean gain of 3.8 years in stroke-free survival post-hypercholesterolaemia compared to other patients with stroke and hypercholesterolaemia (Figure 3).

These observations raise many questions, among which are the optimal prescription of statins in patients with hypercholesterolaemia and the role of statins' pleiotropic effects [35] in slowing down and/or preventing the onset of stroke in patients with hypercholesterolaemia. In our study, 44.6% of patients with stroke had a history of hypercholesterolaemia. Among them, 61.1% were

prescribed statins. This indicates that these patients were correctly identified as being at risk of cardiovascular disease and were prescribed statins almost twice as much as other patients with hypercholesterolaemia (32.7%). If stroke could not be avoided for these patients, our data show that the onset of stroke was significantly delayed in this subgroup of patients compared to patients without statin prescription. The post hoc analysis in patients with a history of stroke also suggests that a significant proportion of these patients could have benefited from statin therapy, potentially leading to a reduced risk of stroke.

This perspective supposes, however, that statin therapy is further prescribed to patients with untreated hypercholesterolaemia, which represents 13.0% (n=110,522) of the registry population and does not align with the current prevention policy. Another perspective reveals that only 1.5% of patients with untreated hypercholesterolaemia experienced stroke, which is significantly lower than in patients with prescribed statins (Table 1), but is also slightly higher than the prevalence of stroke in the registry (1.2%). The multivariable analysis of patients' sociodemographic characteristics and stroke risk factors on statin prescription also shows that statins are prescribed according to current guidelines [22], that is, in patients with a history of cardiovascular disease and associated risk factors, including hypertension and diabetes. This analysis also reveals that female patients and patients of Black ethnicity are less likely to be prescribed statin therapy compared to male patients and patients of White and Asian ethnicity, respectively.

This tendency may be due to implicit ethnicity-based biases by healthcare providers [36], misconceptions that women are at lower risk of cardiovascular disease [37, 38], or patient perceptions and beliefs regarding cardiovascular risk and statin therapy [39]. This tendency may also be linked with our previous observation that patients of Black ethnicity with hypercholesterolaemia had a higher risk of stroke compared to their counterparts of White and Asian ethnicity [40].

Of note, our analysis is based on recorded statin prescriptions. In other words, depending on treatment adherence and treatment gaps [27], prescriptions overestimate the actual exposure to statin therapy. As a consequence, it is likely that the true effect of statin therapy on the cumulative incidence of stroke is underestimated in our study. Conversely, depending on gender and ethnic patterns in statin therapy adherence, which appears to be lower in racial subgroups and women [41], it is also likely that the effect of gender and ethnicity on the risk of stroke is distorted. For instance, the higher risk of stroke observed in patients of non-White ethnicity is likely to be confounded with lower adherence in these patients, whereas the gender effect is likely to be underestimated as female patients exhibit both a lower risk of stroke and lower adherence to statin therapy.

More generally, in addition to potential bias, including immortal time bias and adherence bias, as discussed above, limitations and strengths of our study relate to both the use of routinely collected primary care electronic health records and the population under study. Although primary care electronic health records are widely regarded as a dependable data source and are increasingly utilised for research, surveillance, and public health planning [42, 43], the accuracy and completeness of recorded information may raise concerns. For example, records

such as patients' current smoking status, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and QRISK3 score were not available in the electronic health records considered in this study.

Finally, the characteristics of the analysed population are important aspects to consider, as they may either support or limit specific study objectives. On one hand, the relative geographical and environmental uniformity within Lambeth borough, along with its diverse population, facilitates the identification of biases, such as inequalities in statin prescription practices. These characteristics should, however, be taken into account when attempting to generalise study results into other settings.

Conclusion

This study focused on statin prescription and the risk of stroke in patients with diagnosed hypercholesterolaemia. Overall, our results show a protective effect of statins on stroke risk in these patients, either by preventing strokes or delaying their onset. Further insights reveal that guidelines for statin prescription are generally well followed by general practitioners, although post hoc analysis suggests that a small proportion of patients with untreated hypercholesterolaemia may have benefited from statin therapy.

In line with NICE (updated) guidelines on statin prescription, our results further suggest that in uncertain or complex situations, and according to patients' informed preference, comorbidity, sociodemographic characteristics, or ethnicity, statin therapy prescription may be extended with potential benefit, even if patients do not present a 10-year cardiovascular risk higher than 10%. Finally, we recommend that further efforts be made to address disparities observed in statin prescription across gender groups and ethnic groups.

Author contribution

MD designed the study (conceptualisation and methodology); AD and MA acquired the data; MD carried out data curation; MD and MA conducted investigations; MD developed computer code and performed formal analysis, including data visualisation and validation; MD, MA, and AD interpreted the data. MD drafted the manuscript, and AD supervised the research. MD, MA, and AD reviewed, edited, and approved the final version of the manuscript.

Data availability

Data supporting this study can be obtained from a third party, subject to IRB approval, but are not publicly available.

Funding

This project is funded by Guy's and St Thomas Charity 'MLTC Challenge Fund' (grant number EIC180702). The funder had no role in the study design, data collection, analysis, interpretation, or writing of the report, nor in the decision to submit the paper for publication.

Acknowledgments

We would like to express our deepest gratitude to Pr Mark Ashworth, who sadly passed away during the preparation of this manuscript. His contributions to this research were invaluable, and his dedication to the field continues to inspire us. This work is dedicated to his memory.

Declarations of interest

There are no competing interests for any author.

Table 1: *Sociodemographics and of stroke risk factors according to hypercholesterolaemia and statins prescription*

Patient characteristis		Statins		Stroke		Total
		Not prescribed	Prescribed	Not recorded	Recorded	
Total N (%)		110522 (66.5)	55602 (33.5)	161734 (97.4)	4390 (2.6)	166124
Age at end of follow-up	Median (IQR)	50.7 (19.8)	67.2 (19.5)	56.1 (22.0)	71.3 (20.5)	56.2 (22.2)
Gender	Male	53001 (48.0)	29116 (52.4)	79923 (49.4)	2194 (50.0)	82117 (49.4)
	Female	57518 (52.0)	26486 (47.6)	81808 (50.6)	2196 (50.0)	84004 (50.6)
Ethnicity	White	61809 (55.9)	28584 (51.4)	88094 (54.5)	2299 (52.4)	90393 (54.4)
	Black	22568 (20.4)	13807 (24.8)	35208 (21.8)	1167 (26.6)	36375 (21.9)
	Asian	8014 (7.3)	5857 (10.5)	13545 (8.4)	326 (7.4)	13871 (8.3)
	Mixed	4323 (3.9)	1807 (3.2)	5997 (3.7)	133 (3.0)	6130 (3.7)
	Other	3329 (3.0)	1334 (2.4)	4597 (2.8)	66 (1.5)	4663 (2.8)
	Unknown	10479 (9.5)	4213 (7.6)	14293 (8.8)	399 (9.1)	14692 (8.8)
IMD local quintile	1 (most deprived)	22683 (20.8)	13134 (23.9)	34680 (21.7)	1137 (26.1)	35817 (21.8)
	2	22449 (20.5)	12047 (21.9)	33548 (21.0)	948 (21.7)	34496 (21.0)
	3	19876 (18.2)	9253 (16.8)	28428 (17.8)	701 (16.1)	29129 (17.7)
	4	20899 (19.1)	9528 (17.3)	29744 (18.6)	683 (15.7)	30427 (18.5)
	5 (least deprived)	23346 (21.4)	11107 (20.2)	33561 (21.0)	892 (20.5)	34453 (21.0)
Age at record of Hypercholesterolaemia	Median (IQR)	43.5 (16.4)	55.3 (18.3)	46.8 (18.1)	63.1 (19.4)	47.2 (18.4)
Hypertension	No	91292 (82.6)	22199 (39.9)	112064 (69.3)	1427 (32.5)	113491 (68.3)
	Yes	19230 (17.4)	33403 (60.1)	49670 (30.7)	2963 (67.5)	52633 (31.7)
Diabetes	No	105454 (95.4)	33750 (60.7)	136117 (84.2)	3087 (70.3)	139204 (83.8)
	Yes	5068 (4.6)	21852 (39.3)	25617 (15.8)	1303 (29.7)	26920 (16.2)
CKD 3-5[a]	No	107673 (97.4)	46924 (84.4)	150932 (93.3)	3665 (83.5)	154597 (93.1)
	Yes	2849 (2.6)	8678 (15.6)	10802 (6.7)	725 (16.5)	11527 (6.9)
Smoking ever	No	54301 (49.1)	22363 (40.2)	74869 (46.3)	1795 (40.9)	76664 (46.1)
	Yes	56221 (50.9)	33239 (59.8)	86865 (53.7)	2595 (59.1)	89460 (53.9)
Obesity (moderate to severe)	No	78984 (71.5)	28701 (51.6)	104936 (64.9)	2749 (62.6)	107685 (64.8)
	Yes	31538 (28.5)	26901 (48.4)	56798 (35.1)	1641 (37.4)	58439 (35.2)
Stroke	No	108813 (98.5)	52921 (95.2)	161734(100)	0 (0)	161734 (97.4)
	Yes	1709 (1.5)	2681 (4.8)	0 (0)	4390(100)	4390 (2.6)
Atrial Fibrillation	No	108830 (98.5)	51583 (92.8)	156578 (96.8)	3835 (87.4)	160413 (96.6)
	Yes	1692 (1.5)	4019 (7.2)	5156 (3.2)	555 (12.6)	5711 (3.4)
History of heart disease[c]	No	108768 (98.4)	44298 (79.7)	149776 (92.6)	3290 (74.9)	153066 (92.1)
	Yes	1754 (1.6)	11304 (20.3)	11958 (7.4)	1100 (25.1)	13058 (7.9)
History of cardiovascular disease[e]	No	107268 (97.1)	41381 (74.4)	146113 (90.3)	2536 (57.8)	148649 (89.5)
	Yes	3254 (2.9)	14221 (25.6)	15621 (9.7)	1854 (42.2)	17475 (10.5)
Diabetes*[d] or CKD 3-5	No	103913 (94.0)	30042 (54.0)	131263 (81.2)	2692 (61.3)	133955 (80.6)
	Yes	6609 (6.0)	25560 (46.0)	30471 (18.8)	1698 (38.7)	32169 (19.4)
Statins prescription	Yes	0 (0)	110522(100)	108813 (67.3)	1709 (38.9)	110522 (66.5)
	No	55602(100)	0 (0)	52921 (32.7)	2681 (61.1)	55602 (33.5)

[a] Chronic Kidney Disease Stage 3-5

[b] Myocardial infarction, Peripheral Arterial/Vascular Disease, Heart Failure, Coronary Heart Disease

[c] History of Deart Disease, Atrial Fibrillation, Transient Ischemic Attack

[d] Diabetes after 40 years old or for more than 10 years

References

[1] Joshua Willey and Marco Gonzalez-Castellon. Cholesterol level and stroke: a complex relationship. *JAMA internal medicine*, 173(19):1765–1766, 2013.

[2] Yurong Zhang, Jaakko Tuomilehto, Pekka Jousilahti, Yujie Wang, Riitta Antikainen, and Gang Hu. Total and high-density lipoprotein cholesterol and stroke risk. *Stroke*, 43:1768–1774, 7 2012.

[3] LB Goldstein, P Amarenco, M Szarek, A Callahan III, M Hennerici, H Sillesen, JA Zivin, and KMA Welch. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. *Neurology*, 70(24_part_2):2364–2370, 2008.

[4] Xiang Wang, Yan Dong, Xiangqian Qi, Chengguang Huang, and Lijun Hou. Cholesterol levels and risk of hemorrhagic stroke: A systematic review and meta-analysis. *Stroke*, 44:1833–1839, 7 2013.

[5] S. MacMahon, S. Duffy, A. Rodgers, S. Tominaga, L. Chambless, G. De Backer, D. De Bacquer, M. Kornitzer, P. Whincup, S. G. Wannamethee, R. Morris, N. Wald, J. Morris, M. Law, M. Knuiman, H. Bartholomew, G. Davey Smith, P. Sweetnam, P. Elwood, J. Yarnell, R. Kronmal, D. Kromhout, S. Sutherland, J. Keil, G. Jensen, P. Schnohr, C. Hames, A. Tyroler, A. Aromaa, P. Knekt, A. Reunanen, J. Tuomilehto, P. Jousilahti, E. Vartiainen, P. Puska, T. Kuznetsova, T. Richart, J. Staessen, L. Thijs, T. Jorgensen, T. Thomsen, D. Sharp, J. D. Curb, N. Qizilbash, H. Iso, S. Sato, A. Kitamura, Y. Naito, A. Benetos, L. Guize, U. Goldbourt, M. Tomita, Y. Nishimoto, T. Murayama, M. Criqui, C. Davis, C. Hart, D. Hole, C. Gillis, D. Jacobs, H. Blackburn, R. Luepker, J. Neaton, L. Eberly, C. Cox, D. Levy, R. D'Agostino, H. Silbershatz, A. Tverdal, R. Selmer, T. Meade, K. Garrow, J. Cooper, F. Speizer, M. Stampfer, A. Menotti, A. Spagnolo, I. Tsuji, Y. Imai, T. Ohkubo, S. Hisamichi, L. Haheim, I. Holme, I. Hjermann, P. Leren, P. Ducimetiere, J. Empana, K. Jamrozik, R. Broadhurst, G. Assmann, H. Schulte, C. Bengtsson, C. Björkelund, L. Lissner, P. Sorlie, M. Garcia-Palmieri, E. Barrett-Connor, R. Langer, K. Nakachi, K. Imai, X. Fang, S. Li, R. Buzina, A. Nissinen, C. Aravanis, A. Dontas, A. Kafatos, H. Adachi, H. Toshima, T. Imaizumi, S. Nedeljkovic, M. Ostojic, Z. Chen, H. Tunstall-Pedoe, T. Nakayama, N. Yoshiike, T. Yokoyama, C. Date, H. Tanaka, J. Keller, K. Bonaa, E. Arnesen, E. Rimm, M. Gaziano, J. E. Buring, C. Hennekens, S. Törnberg, J. Carstensen, M. Shipley, D. Leon, M. Marmot, J. Armitage, C. Baigent, R. Clarke, R. Collins, J. Emberson, J. Halsey, M. Landray, S. Lewington, A. Palmer, S. Parish, R. Peto, P. Sherliker, and G. Whitlock. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet (London, England)*, 370:1829–1839, 12 2007.

[6] Melissa A Austin, Carolyn M Hutter, Ron L Zimmern, and Steve E Humphries. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a huge prevalence review. *American journal of epidemiology*, 160(5):407–420, 2004.

[7] F. Barkas, M. Elisaf, and H. Milionis. Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. *Atherosclerosis*, 243(1):60–64, 2015.

[8] A. Hovland, L. Mundal, J. Igland, M. B. Veierød, K. B. Holven, M. P. Bogsrud, G. S. Tell, T. P. Leren, and K. Retterstøl. Risk of ischemic stroke and total cerebrovascular disease in familial hypercholesterolemia: A register study from norway. *Stroke*, 50(1):172–174, 2018.

[9] S. O. Beheshti, C. M. Madsen, A. Varbo, M. Benn, and B. G. Nordestgaard. Relationship of familial hypercholesterolemia and high low-density lipoprotein cholesterol to ischemic stroke: Copenhagen general population study. *Circulation*, 138(6):578–589, 2018.

[10] Hiroyasu Iso, David R. Jacobs, Deborah Wentworth, James D. Neaton, and Jerome D. Cohen. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. *New England Journal of Medicine*, 320:904–910, 4 1989.

[11] Epidemiological Studies Unit. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. *Lancet*, 366(9493):1267–1278, 2005.

[12] C. Baigent, L. Blackwell, J. Emberson, L. E. Holland, C. Reith, N. Bhala, R. Peto, E. H. Barnes, A. Keech, J. Simes, R. Collins, J. De Lemos, E. Braunwald, M. Blazing, S. Murphy, J. R. Downs, A. Gotto, M. Clearfield, H. Holdaas, D. Gordon, B. Davis, M. Koren, B. Dahlof, N. Poulter, P. Sever, R. H. Knopp, B. Fellström, A. Jardine, R. Schmieder, F. Zannad, U. Goldbourt, E. Kaplinsky, H. M. Colhoun, D. J. Betteridge, P. N. Durrington, G. A. Hitman, J. Fuller, A. Neil, C. Wanner, V. Krane, F. Sacks, L. Moyé, M. Pfeffer, C. M. Hawkins, P. Barter, L. Tavazzi, A. Maggioni, R. Marchioli, G. Tognoni, M. G. Franzosi, H. Bloomfield, S. Robins, J. Armitage, S. Parish, P. Sleight, T. R. Pedersen, P. M. Ridker, R. Holman, T. Meade, S. MacMahon, I. Marschner, A. Tonkin, J. Shaw, P. W. Serruys, H. Nakamura, G. Knatterud, C. Furberg, R. Byington, P. Macfarlane, S. Cobbe, I. Ford, M. Murphy, G. J. Blauw, C. Packard, J. Shepherd, J. Kjekshus, L. Wilhelmsen, C. Cannon, L. Bowman, A. Baxter, M. Landray, J. La Rosa, J. Rossouw, J. Probstfield, M. Flather, J. Kastelein, C. Newman, C. Shear, J. Tobert, J. Varigos, H. White, S. Yusuf, M. Mellies, M. McGovern, J. Barclay, R. Belder, Y. Mitchel, T. Musliner, J. C. Ansquer, M. Llewellyn, M. Bortolini, G. Brandrup-Wognsen, B. Bryzinski, G. Olsson, J. Pears, D. De Micco, G. Buck, W. G. Herrington, P. M. Kearney, A. Kirby, D. A. Lewis, C. Pollicino, and T. Sourjina. Efficacy and safety of more intensive lowering of ldl cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. *The Lancet*, 376:1670–1681, 11 2010.

[13] B. Mihaylova, J. Emberson, L. Blackwell, A. Keech, J. Simes, E. H. Barnes, M. Voysey, A. Gray, R. Collins, C. Baigent, J. De Lemos, E. Braunwald, M. Blazing, S. Murphy, J. R. Downs, A. Gotto, M. Clearfield, H. Holdaas, D. Gordon, B. Davis, M. Koren, B. Dahlof, N. Poulter, P. Sever, R. H. Knopp, B. Fellstrom, A. Jardine, R. Schmieder, F. Zannad, U. Goldbourt, E. Kaplinsky, H. M. Colhoun, D. J. Betteridge, P. N. Durrington, G. A. Hitman, J. Fuller, A. Neil, C. Wanner, V. Krane, F. Sacks, L. Moye, M. Pfeffer, C. M. Hawkins, J. Kjekshus, H. Wedel, J. Wikstrand, P. Barter, L. Tavazzi, A. Maggioni, R. Marchioli, G. Tognoni, M. G. Franzosi, H. Bloomfield, S. Robins, J. Armitage, S. Parish, R. Peto, P. Sleight, T. R. Pedersen, P. M. Ridker, R. Holman, T. Meade, S. MacMahon, I. Marschner, A. Tonkin, J. Shaw, P. W. Serruys, H. Nakamura, G. Knatterud, C. Furberg, R. Byington, P. MacFarlane, S. Cobbe, I. Ford, M. Murphy, G. J. Blauw, C. Packard, J. Shepherd, L. Wilhelmsen, C. Cannon, L. Bowman, M. Landray, J. La Rosa, J. Rossouw, J. Probstfi Eld, M. Flather, J. Kastelein, C. Newman, C. Shear, J. Tobert, J. Varigos, H. White, S. Yusuf, M. Mellies, M. McGovern, J. Barclay, R. Belder, Merck Y. Mitchel, T. Musliner, J. C. Ansquer, Bayer M. Llewellyn, Novartis Pharma, M. Bortolini, G. Brandrup-Wognsen, B. Bryzinski, G. Olsson, J. Pears, D. DeMicco, A. Baxter, N. Bhala, G. Buck, W. G. Herrington, L. E. Holland, P. M. Kearney, A. Kirby, D. A. Lewis, C. Pollicino, C. Reith, and T. Sourjina. The effects of lowering ldl cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *The Lancet*, 380:581–590, 8 2012.

[14] Karianne Svendsen, Thomas Olsen, Kathrine J. Vinknes, Liv J. Mundal, Kirsten B. Holven, Martin P. Bogsrud, Trond P. Leren, Jannicke Igland, and Kjetil Retterstøl. Risk of stroke in genetically verified familial hypercholesterolemia: A prospective matched cohort study. *Atherosclerosis*, 358:34–40, 10 2022.

[15] Malcolm Law and Alicja R. Rudnicka. Statin safety: A systematic review. *The American Journal of Cardiology*, 97:S52–S60, 4 2006.

[16] Christina Reith, Colin Baigent, Lisa Blackwell, Jonathan Emberson, Enti Spata, Kelly Davies, Heather Halls, Lisa Holland, Kate Wilson, Jane Armitage, et al. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. *The Lancet*, 400(10355):832–845, 2022.

[17] Emily Herrett, Elizabeth Williamson, Kieran Brack, Danielle Beaumont, Alexander Perkins, Andrew Thayne, Haleema Shakur-Still, Ian Roberts, Danielle Prowse, Ben Goldacre, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. *bmj*, 372, 2021.

[18] Naveed Sattar, David Preiss, Heather M Murray, Paul Welsh, Brendan M Buckley, Anton JM de Craen, Sreenivasa Rao Kondapally Seshasai, John J McMurray, Dilys J Freeman, J Wouter Jukema, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *The Lancet*, 375(9716):735–742, 2010.

[19] Borislava Mihaylova, Runguo Wu, Junwen Zhou, Claire Williams, Iryna Schlackow, Jonathan Emberson, Christina Reith, Anthony Keech, John Robson, Richard Parnell, Jane Armitage, Alastair Gray, John Simes, and Colin Baigent. Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the uk: a microsimulation modelling study. *The Lancet Regional Health - Europe*, 40:100887, 5 2024.

[20] Frank LJ Visseren, François Mach, Yvo M Smulders, David Carballo, Konstantinos C Koskinas, Maria Bäck, Athanase Benetos, Alessandro Biffi, José-Manuel Boavida, Davide Capodanno, et al. 2021 esc guidelines on cardiovascular disease prevention in clinical practice: Developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the european society of cardiology and 12 medical societies with the special contribution of the european association of preventive cardiology (eapc). *European heart journal*, 42(34):3227–3337, 2021.

[21] Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah De Ferranti, Joseph Faiella-Tommasino, Daniel E Forman, et al. 2018 aha/acc/aacvpr/aapa/abc/acpm/ada/ags/apha/aspc/nla/pcna guideline on the management of blood cholesterol: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. *Journal of the American College of Cardiology*, 73(24):e285–e350, 2019.

[22] NICE guideline CG181. Cardiovascular disease: risk assessment and reduction, including lipid modification. *Methods*, 2023.

[23] Sam Finnikin, Brian Finney, Rani Khatib, and James McCormack. Statins, risk, and personalised care. *bmj*, 384, 2024.

[24] National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. `https://www.nice.org.uk/guidance/cg181`, 2014. CG181.

[25] Julia Hippisley-Cox, Carol Coupland, and Peter Brindle. Development and validation of qrisk3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. *BMJ*, 357:j2099, 2017.

[26] National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification, 2023. Accessed: 2024-02-11.

[27] Alexander Pate, Rachel A Elliott, Georgios Gkountouras, Alexander Thompson, Richard Emsley, and Tjeerd van Staa. The impact of statin discontinuation and restarting rates on the optimal time to initiate statins and on the number of cardiovascular events prevented. *Pharmacoepidemiology and Drug Safety*, 29(6):644–652, 2020.

[28] Ralph Kwame Akyea, Joe Kai, Nadeem Qureshi, Barbara Iyen, and Stephen F. Weng. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. *Heart*, 105:975–981, 7 2019.

[29] Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. *The Lancet Neurology*, 8:453–463, 5 2009.

[30] NHS Digital. Quality and Outcomes Framework (QOF) Business Rules v38: 2017-2018 October Code Release, October 2018. Available from: `https://webarchive.nationalarchives.gov.uk/ukgwa/20221104222820/https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-collections/quality-and-outcomes-framework-qof#quality-and-outcome-framework-business-rules`.

[31] John D Kalbfleisch and Ross L Prentice. *The statistical analysis of failure time data*. John Wiley & Sons, 2011.

[32] Jason P Fine and Robert J Gray. A proportional hazards model for the subdistribution of a competing risk. *Journal of the American statistical association*, 94(446):496–509, 1999.

[33] R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2023.

[34] NHS England. Privacy Notice - NHS England and NHS Improvement. https://www.england.nhs.uk/contact-us/privacy-notice/find-out-what-a-privacy-notice-is/. Accessed on 2024-04-01.

[35] James K Liao and Ulrich Laufs. Pleiotropic effects of statins. *Annu. Rev. Pharmacol. Toxicol.*, 45(1):89–118, 2005.

[36] Irene V Blair, Edward P Havranek, David W Price, Rebecca Hanratty, Diane L Fairclough, Tillman Farley, Holen K Hirsh, and John F Steiner. Assessment of biases against latinos and african americans among primary care providers and community members. *American journal of public health*, 103(1):92–98, 2013.

[37] Lori Mosca, Elizabeth Barrett-Connor, and Nanette Kass Wenger. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. *Circulation*, 124(19):2145–2154, 2011.

[38] Min Zhao, Mark Woodward, Ilonca Vaartjes, Elizabeth RC Millett, Kerstin Klipstein-Grobusch, Karice Hyun, Cheryl Carcel, and Sanne AE Peters. Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis. *Journal of the American Heart Association*, 9(11):e014742, 2020.

[39] Michael G Nanna, Ann Marie Navar, Pearl Zakroysky, Qun Xiang, Anne C Goldberg, Jennifer Robinson, Veronique L Roger, Salim S Virani, Peter WF Wilson, Joseph Elassal, et al. Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use: insights from the patient and provider assessment of lipid management registry. *JAMA cardiology*, 3(8):739–748, 2018.

[40] Marc Delord, Mark Ashworth, and Abdel Douiri. Does ethnicity alters the risk of stroke in patients with modifiable cardiometabolic risk factors? *medRxiv*, 2024.

[41] Jennifer Lewey, William H. Shrank, Ashna D.K. Bowry, Elaine Kilabuk, Troyen A. Brennan, and Niteesh K. Choudhry. Gender and racial disparities in adherence to statin therapy: A meta-analysis. *American Heart Journal*, 165:665–678.e1, 5 2013.

[42] Nicole Gray Weiskopf and Chunhua Weng. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. *Journal of the American Medical Informatics Association*, 20(1):144–151, 2013.

[43] Clemens Scott Kruse, Anna Stein, Heather Thomas, and Harmander Kaur. The use of electronic health records to support population health: a systematic review of the literature. *Journal of medical systems*, 42(11):214, 2018.